Halozyme Therapeutics, Inc. (HALO) on Decifer

Decifer ranks HALO number 204 of 268 tracked names on durable business quality.

Why it ranks here

• Sales are growing about 38% a year, faster than 85 in 100 companies we measure.
• It keeps about 46 cents of every sales dollar as cash, safer than 98 in 100 companies we measure.
• It earns about 14% a year on the money put into the business, better than 72 in 100 companies we measure.
• It costs about 38 times its yearly profit; the middle of its industry is 21. Cheaper than 19 in 100 companies we measure, against their own industries.

The current read

The evidence on HALO lines up on the supportive side: the intelligence feed flags this name as connected to what is moving markets now. The independent signals we track are telling the same story.

Themes

• Next-Gen Genetic & RNA/Antibody Therapeutics: Platform breakthroughs in RNA interference, redosable gene therapy and antibody engineering are converting once-undruggable and orphan targets into commercial therapies.

Read the full HALO research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.